CN112587665B - AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 - Google Patents
AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 Download PDFInfo
- Publication number
- CN112587665B CN112587665B CN202110248587.8A CN202110248587A CN112587665B CN 112587665 B CN112587665 B CN 112587665B CN 202110248587 A CN202110248587 A CN 202110248587A CN 112587665 B CN112587665 B CN 112587665B
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- hif
- alpha
- pneumonia
- fibroblasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 65
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 title claims abstract description 36
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title description 3
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 47
- 230000014509 gene expression Effects 0.000 claims abstract description 33
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 206010035737 Pneumonia viral Diseases 0.000 claims abstract description 30
- 208000009421 viral pneumonia Diseases 0.000 claims abstract description 30
- OJYIBEYSBXIQOP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methoxyphenyl)propan-2-yl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)(C)C1=CC=C(OC)C=C1 OJYIBEYSBXIQOP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims abstract description 13
- 108091005664 ADAMTS4 Proteins 0.000 claims abstract description 12
- 102100027995 Collagenase 3 Human genes 0.000 claims abstract description 12
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims abstract description 12
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims abstract description 12
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 claims abstract description 12
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims abstract description 12
- 102100028437 Versican core protein Human genes 0.000 claims abstract description 12
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 claims abstract description 11
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 claims abstract description 8
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 claims abstract description 8
- 102100027400 A disintegrin and metalloproteinase with thrombospondin motifs 4 Human genes 0.000 claims abstract 2
- 101000851054 Homo sapiens Elastin Proteins 0.000 claims abstract 2
- 101000687673 Homo sapiens Small integral membrane protein 6 Proteins 0.000 claims abstract 2
- 102100024806 Small integral membrane protein 6 Human genes 0.000 claims abstract 2
- 206010035664 Pneumonia Diseases 0.000 claims description 27
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 10
- 229960004671 enzalutamide Drugs 0.000 claims description 10
- KRBMOYIWQCZVHA-INIZCTEOSA-N 4-[3-[4-[(2s)-2,3-dihydroxypropoxy]phenyl]-4,4-dimethyl-5-oxo-2-sulfanylideneimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)N(C=2C=CC(OC[C@@H](O)CO)=CC=2)C(=S)N1C1=CC=C(C#N)C(C(F)(F)F)=C1 KRBMOYIWQCZVHA-INIZCTEOSA-N 0.000 claims description 9
- 241000711573 Coronaviridae Species 0.000 claims description 9
- 229940073452 rezvilutamide Drugs 0.000 claims description 9
- KCBJGVDOSBKVKP-UHFFFAOYSA-N 4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)N(C=2C=NC(CCCC=3OC=CN=3)=CC=2)C(=S)N1C1=CC=C(C#N)C(C(F)(F)F)=C1F KCBJGVDOSBKVKP-UHFFFAOYSA-N 0.000 claims description 8
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 claims description 8
- 229940125286 pruxelutamide Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000025721 COVID-19 Diseases 0.000 claims description 6
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 claims description 6
- JMEYDSHPKCSIJC-UHFFFAOYSA-N 1-[4-[2-[4-[1-[3-(trifluoromethyl)-7,8-dihydro-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]piperidin-4-yl]phenoxy]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC=C(C2CCN(CC2)C=2CCC=3N(C(=NN=3)C(F)(F)F)N=2)C=C1 JMEYDSHPKCSIJC-UHFFFAOYSA-N 0.000 claims description 5
- 102000004889 Interleukin-6 Human genes 0.000 claims description 5
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 5
- 229950007511 apalutamide Drugs 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 229950001379 darolutamide Drugs 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 abstract description 31
- 230000004913 activation Effects 0.000 abstract description 12
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 abstract description 8
- 239000001301 oxygen Substances 0.000 abstract description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 7
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 5
- 230000035897 transcription Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000013518 transcription Methods 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 230000009325 pulmonary function Effects 0.000 abstract 1
- 102000006306 Antigen Receptors Human genes 0.000 description 65
- 108010083359 Antigen Receptors Proteins 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 19
- 206010021143 Hypoxia Diseases 0.000 description 18
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 11
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 11
- 102000016942 Elastin Human genes 0.000 description 11
- 108010014258 Elastin Proteins 0.000 description 11
- 102000051403 ADAMTS4 Human genes 0.000 description 10
- 229920002549 elastin Polymers 0.000 description 10
- 230000001146 hypoxic effect Effects 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 229950003400 galeterone Drugs 0.000 description 5
- 208000018875 hypoxemia Diseases 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 4
- 229960003473 androstanolone Drugs 0.000 description 4
- 238000000749 co-immunoprecipitation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 241001678559 COVID-19 virus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- -1 COL3a1 Proteins 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000005820 Prochloraz Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 102000001307 androgen receptors Human genes 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 229960003089 pramipexole Drugs 0.000 description 2
- TVLSRXXIMLFWEO-UHFFFAOYSA-N prochloraz Chemical compound C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl TVLSRXXIMLFWEO-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000026425 severe pneumonia Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010091175 Matriptase Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 244000000001 Virome Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Abstract
本发明公开了HIF‑1α抑制剂或AR抑制剂或两者联合在抑制炎症因子风暴、预防或治疗病毒性肺炎中的应用。本发明发现HIF‑1α抑制剂与AR抑制剂通过有效抑制HIF‑1α与AR相互结合,在成纤维细胞中的低氧环境下,阻止炎症因子风暴相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)的转录,使得相关基因的表达量降低,进而抑制低氧环境下肺部成纤维细胞的活化。肺部成纤维细胞的活化被抑制能够让严重呼吸道感染的急性呼吸窘迫综合征(ARDS)患者维持肺功能、改善临床疗效;并且,HIF‑1α抑制剂与AR抑制剂具有成本低,毒副作用小,疗效显著的优点,为病毒性肺炎的治疗提供了新策略。
Description
技术领域
本发明属于病毒性肺炎治疗技术领域,具体涉及AR抑制剂和/或HIF-1α抑制剂在制备抑制炎症因子风暴药物、预防或治疗病毒性肺炎中的应用。
背景技术
严重呼吸道感染可导致急性呼吸窘迫综合征(ARDS)。目前还没有有效的药物治疗已经被证明可以改善ARDS患者的预后。虽然宿主的炎症反应限制了病原体的传播并最终清除了病原体,但免疫病理是导致组织损伤和ARDS的主要原因之一。此外,肺成纤维细胞在病毒肺炎中发挥重要的作用。呼吸道病毒感染会引起不同的成纤维细胞激活状态,包括细胞外基质(ECM)合成、损伤反应和干扰素应答状态。在严重流感病毒感染期间,损伤反应的肺成纤维细胞的过度活动诱发致命的免疫病理。通过产生ECM重塑酶和炎症因子,损伤反应的成纤维细胞改变肺部微环境,促进免疫细胞的浸润,损害肺功能。一种靶向损伤反应性肺成纤维细胞的治疗剂,可为严重呼吸道感染后维持肺功能和改善临床疗效提供一种有前景的方法。
病毒性肺炎(Viral pneumonia)是由上呼吸道病毒感染、向下蔓延所致的肺部炎症,根据症状严重程度,临床分为轻型、中型、重型和危重型。轻度病例临床症状轻微但没有肺炎的影像学表现;中度病例伴随发烧,呼吸道症状和肺炎影像学表现;重症病例出现低氧血症,且静止时的氧饱和度<93%或PaO2/FiO2<300mmHg;危重症病例则会需要机械通气或ICU重症监护等。病毒性肺炎重症与否的关键在于低氧血症,低氧血症会使得肺部产生缺氧的环境;同时,重型患者会快速进展为急性呼吸窘迫综合症(ARDS)、脓毒症休克、难以纠正的代谢性酸中毒、出凝血功能障碍及多器官功能衰竭等。
病毒性肺炎病毒的感染会导致急性呼吸窘迫综合征(ARDS)从而引发肺组织的炎症反应,炎症反应产生的多种刺激物质使得正常的肺成纤维细胞活化。活化的成纤维细胞可产生大量炎症因子如白介素6以及基质蛋白酶如MMP2等。同时,肺成纤维细胞的活化使得病毒性肺炎临床症状进一步加重。有文献报道称为探究确定呼吸道感染者肺部成纤维细胞活化的上游刺激,通过使用人季节性H3N2病毒或禽类H5N6、H7N9病毒在体外感染正常人支气管上皮细胞(NHBES)是否足以在共培养中驱动人肺成纤维细胞中的炎症转录程序。结果表明NHBEs的感染诱导了成纤维细胞中富含炎症状态的基因的表达,这些基因包括细胞因子白介素6(IL6);基质蛋白酶基质金属蛋白酶2(MMP2)、基质金属蛋白酶13(MMP13)和ADAMTS4;细胞外基质蛋白酶弹性蛋白(ELN)、多功能蛋白聚糖(VCAN)、Ⅲ型胶原蛋白基因α1(COL3A1);血管生长因子(VEGFA)等。我们研究发现(Suppression of Androgen Receptor(AR)-ACE2/TMPRSS2 Axis by AR Antagonists May Be Therapeutically Beneficialfor Male COVID-19 Patients,January 2020,SSRN Electronic Journal),AR抑制剂普克鲁胺可以靶向AR-ACE2/TMPRSS2信号轴,通过抑制血管紧张素转换酶2(ACE2)和跨膜丝氨酸蛋白酶2(TMPRSS2)的表达,来降低或阻断COVID-19进入宿主细胞。可以看出,调控ACE2 和TMPRSS2表达主要是影响新冠感染。同时,现有研究披露(Remdesivir in adults withsevere COVID-19: a randomised, double-blind, placebo-controlled, multicentretrial,Vol 395 May 16,2020,the lancet,),瑞德西韦用于新冠重症临床实验(NCT04257656)的失败也表明单独抗病毒感染并不能改善重症患者的转归,造成病毒性肺炎患者重症化的最主要原因是低氧血症。
因此,探寻一种能够抑制低血氧症导致的成纤维细胞活化的药物对于治疗病毒性肺炎特别是中重症病毒性肺炎是迫切需要的。
发明内容
为了解决上述技术问题,筛选出针对病毒性肺炎特别是具有低血氧症的中重症肺炎治疗的有效药物,发明人在研究中发现病毒性肺炎患者的肺成纤维细胞中HIF-1α有较高的表达水平,且HIF-1α与AR相互结合形成的复合物能够结合在相关基因的启动子上,从而在转录水平影响相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)的表达。
第一方面,本发明提供了AR抑制剂和/或HIF-1α抑制剂在制备抑制炎症因子风暴药物中的应用,所述抑制剂抑制成纤维细胞中AR、HIF-1α复合物的形成。
在某些实施例中,所述成纤维细胞处于低氧环境。
在某些实施例中,通过抑制成纤维细胞中AR、HIF-1α复合物的形成影响炎症相关基因的表达,所述相关基因选自: IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA。
在某些实施例中,所述炎症因子风暴由病毒性肺炎引起。
在某些实施例中,所述病毒性肺炎为中症或重症。
在某些实施例中,所述HIF-1α抑制剂选自KC7F2、LW 6、PX-478 2HCI中的一种或多种。
在某些实施例中,所述AR抑制剂选自恩杂鲁胺(Enzalutamide)、阿帕鲁胺(Apalutamide)、达洛鲁胺(Darolutamide)、普克鲁胺(Proxalutamide)、加来特龙(Galeterone)、AZD3514、SHR-3680中的一种或多种。
第二方面,本发明还提供了AR抑制剂和/或HIF-1α抑制剂在制备预防或治疗病毒性肺炎药物中的应用。
在某些实施例中,所述病毒性肺炎为呼吸道合胞病毒肺炎、甲型流感病毒肺炎、新型冠状病毒肺炎。
在某些实施例中,所述病毒性肺炎为中、重症肺炎。
在某些实施例中,所述HIF-1α抑制剂选自KC7F2、LW 6、PX-478 2HCI中的一种或多种。
在某些实施例中,所述AR抑制剂选自恩杂鲁胺(Enzalutamide)、阿帕鲁胺(Apalutamide)、达洛鲁胺(Darolutamide)、普克鲁胺(Proxalutamide)、加来特龙(Galeterone)、AZD3514、SHR-3680中的一种或多种。
第三方面,本发明还提供了一种具有抑制由HIF-1α引起的AR活化的活性化合物的筛选方法,包括以下步骤:
步骤S1,在被检测化合物的存在下,使HIF-1α与AR接触;
步骤S2,检测HIF-1α与AR是否结合;
步骤S3,选择抑制步骤S2所述结合的化合物。
本发明相对与现有技术具有的效果:
1)本发明发现AR抑制剂和/或HIF-1α抑制剂通过有效抑制HIF-1α与AR相互结合,在低氧环境下的成纤维细胞中,阻止相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)的转录,使得相关基因的表达量发生改变,相关基因表达的降低会抑制肺部成纤维细胞的活化,进而能够让严重呼吸道感染的急性呼吸窘迫综合征(ARDS)患者维持肺功能和改善临床疗效。
2)本发明提供的采用HIF-1α抑制剂与AR抑制剂制备抑制炎症因子风暴药物、预防或治疗病毒性肺炎的药物,具有成本低,毒副作用小,疗效显著的优点,为病毒性肺炎的治疗提供了新策略。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式描述中所需要使用的附图作简单地介绍。
图1为新型冠状病毒肺炎感染者的肺成纤维细胞中HIF-1α表达量。
图2为新型冠状病毒肺炎感染者的肺成纤维细胞中HIF-1α表达量放大图。
图 3A为新型冠状肺炎重症患者和新型冠状肺炎未感染者的肺成纤维细胞中ACE2和TMPRSS2基因的表达水平。
图3B为人肺成纤维细胞在添加雄激素培养情况下,缺氧和常氧条件中ACE2和TMPRSS2基因的表达水平。
图 4为人肺成纤维细胞中HIF-1α与AR相互结合形成复合物。
图5A-图5H为实施例5中不同组别抑制剂处理后相关基因的表达水平。
图6A-图6H为实施例6中不同组别抑制剂处理后相关基因的表达水平。
图7A-图7B为实施例7中小鼠存活率及体重变化统计。
具体实施方式
根据下述实施例,可以更好地理解本发明。然而,本领域的技术人员容易理解,实施案例所描述的内容仅用于说明和解释本发明,并不用于限制权利要求书中所详细描述的本发明。除非特别说明,本发明采用的试剂、方法和设备如无特别说明,均为常规方法,所使用的试验材料如无特别说明,均可从商业公司获取。
如本文所用,术语“AR”,雄激素受体,属于核受体超家族中的类固醇受体。AR一般由四个结构域组成:N端转录激活区(NTD)、DNA结合区(DBD)、铰链区和配体结合区(LBD)。
如本文所用,术语“AR抑制剂”指能够用于抑制AR活性的化合物或者组合物。包括但不限于,恩杂鲁胺(Enzalutamide)、阿帕鲁胺(Apalutamide)、达洛鲁胺(Darolutamide)、普克鲁胺(Proxalutamide),加来特龙(Galeterone),AZD3514、SHR-3680。
如本文所用,术语“HIF-1α”,缺氧诱导因子,在细胞中,HIF信号级联反应会受到缺氧状态的影响。在缺氧状态下,通常会让细胞持续的细胞分化。然而,缺氧状态促进了血管新生,对于胚胎中的血管***与癌症肿瘤来说非常重要。
如本文所用,术语“HIF-1α抑制剂”,指能够用于抑制AR活性的化合物或者组合物。包括但不限于,KC7F2、LW 6、PX-478 2HCI中的一种或多种。
如本文所用,术语“AR与HIF-1α复合物”是指HIF-1α通过自身的C端激活域与雄激素受体(AR)的N端结构域相互结合形成的复合物。
如本文所用,术语“炎症因子风暴”又叫细胞因子风暴,是指机体感染微生物后引起体液中多种细胞因子,如α肿瘤坏死因子、白细胞介素-1、白细胞介素-6、白细胞介素-12、α干扰素、β干扰素、γ干扰素等迅速大量产生的现象,是引起急性呼吸窘迫综合征和多脏器衰竭的重要原因。免疫***的日常工作是清除感染,但是如果免疫***被激活到极限程度或者失去控制,就会伤害宿主。
如本文所用,术语“成纤维细胞”是功能活动旺盛的细胞,细胞和细胞核较大,轮廓清楚,核仁大而明显,细胞质弱嗜碱性,具明显的蛋白质合成和分泌活动;处于成熟期或称静止状态的成纤维细胞,胞体变小,呈长梭形,粗面内质网和高尔基复合体均不发达,被称为纤维细胞。在外伤等因素刺激下,部分纤维细胞可重新转变为幼稚的成纤维细胞,其功能活动也得以恢复,参与组织损伤后的修复。
如本文所用,“病毒性肺炎的中、重症”,根据国家卫生委员会《中国COVID-19感染诊治计划指南》第5版,该病例分为4中类型:
(1)轻度病例:临床症状轻微但没有肺炎的影像学表现;
(2)中度病例,伴有发烧,呼吸道症状和肺炎影像表现;
(3)重度病例,以下任何一种,呼吸商RR>30次/分钟的呼吸窘迫,静止时的氧饱和度<93%或PaO2/FiO2<30nnHg(1mmHg=0.133kPa);
(4)危重症病例:具有以下任一种情况,需要机械通气、电机的呼吸衰竭或需要ICU重症监护的其他器官衰竭。
在本发明中,所述中症病毒性肺炎包括上述“(2)中度病例”,所述重症病毒性肺炎包括上述“(3)重度病例”和“(4)危重症病例”。
如本文所用,上述的“治疗”指疾病或病症或其至少一种可辨的症状的减轻、预防或逆转,与所治疗疾病或病症相关的至少一个可测量身体参数的改善、预防或逆转,抑制或减缓疾病或病症的进展,或延迟疾病或病症的发作。
如本文所用,“病毒性肺炎”有流感病毒、副流感病毒、腺病毒、冠状病毒、鼻病毒。呼吸道合胞病毒等。甲型流感病毒和乙型流感病毒主要引发人类流感。甲型流感病毒常常发生抗原变异,从而进一步分为H1N1、H3N2、H5N1、H7N9等亚型。此外,冠状病毒(属于尼多病毒目冠状病毒科)主要造成的人类疾病是呼吸***的感染。而呼吸道感染是病毒性肺炎发病率和死亡率的主要原因。2019冠状病毒病(COVID-19)也称新型冠状病毒,是由严重急性呼吸综合症冠状病毒2(SARS-CoV-2)所致疾病,而SARS-CoV-2就是一种有包膜的单链RNA β属冠状病毒。
如本文所用,“药物”,为采用含有HIF-1α抑制剂与AR抑制剂或其药理学上可接受的药物组合物。根据本发明提供用于治疗病毒性肺炎的药物,所述药物组合物包含HIF-1α抑制剂和AR抑制剂以及药学上可接受的载体或赋形剂。可以制成口服和非口服制剂。口服给药可制成片剂、散剂、颗粒剂、胶囊剂等常用剂型,所用的赋型剂可以为淀粉、乳糖、蔗糖、甘露糖、羟甲基纤维素等中的一种或几种。崩解剂可以为马铃薯淀粉、羟甲基纤维素等中的一种或几种。粘合剂可以为***胶、玉米淀粉、明胶、糊精等中的一种或几种。口服制剂除上述剂型外,还可以制成乳剂、糖浆剂等。非口服制剂可以制成注射剂,可以与注射用水、生理盐水、葡萄糖水制成注射剂,也可以在其中加入一定比例的乙醇、丙醇、乙二醇等。
实施例 1
通过生物信息学Seurat 3.0 和Single R 软件分析新型冠状肺炎重症患者和新型冠状肺炎未感染者单细胞转录组测序数据发现其中感染者肺成纤维细胞中HIF-1α的表达水平远高于未感染者肺成纤维细胞中HIF-1α的表达水平。
新型冠状肺炎感染者单细胞转录组测序数据:GSM4516279,GSM4516280,GSM4516281,GSM4516282 数据网站:https://www.ncbi.nlm.nih.gov/geo。
新型冠状肺炎未感染者单细胞转录组测序数据:E-MTAB-6149、E-MTAB-6653 数据网站:https://www.ebi.ac.uk/arrayexpress。
分析结果如图1所示,表明新型冠状肺炎重症患者肺成纤维细胞中HIF-1α高表达。
实施例2
通过TFmapper与 UCSC Genome Browser 生物信息分析网站工具分析HIF-1α和AR在相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)启动子区域的结合情况。生物信息分析结果表明HIF-1α和AR能够与相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)的启动子区域发生结合,从而对相关基因的转录产生影响。
实施例3
图3A为通过生物信息学Seurat 3.0 和Single R 软件分析新型冠状肺炎重症患者单细胞转录组测序数据和新型冠状肺炎未感染者单细胞转录组测序数据分析ACE2和TMPRSS2基因的表达水平。
新型冠状肺炎感染者单细胞转录组测序数据:GSM4516279,GSM4516280,GSM4516281,GSM4516282 数据网站:https://www.ncbi.nlm.nih.gov/geo。
新型冠状肺炎未感染者单细胞转录组测序数据:E-MTAB-6149、E-MTAB-6653 数据网站:https://www.ebi.ac.uk/arrayexpress。
分析结果如图3A所示,实验结果表明,新型冠状肺炎重症患者和新型冠状肺炎未感染者肺成纤维细胞中ACE2和TMPRSS2基因的表达水平低且组间无明显差异。
图3B为通过添加雄激素(双氢睾酮),在AR通路激活条件下,探究血管紧张素转换酶2(ACE2)和跨膜丝氨酸蛋白酶2(TMPRSS2)的基因表达水平。在缺氧(37℃,1% O2)条件与常氧条件下,添加双氢睾酮(10nM,购自Sigma-Aldrich)的培养基培养人的肺成纤维细胞HFL1,48h后,收集细胞,最后通过实时荧光定量PCR(qPCR)检测相关基因的表达水平。
实验结果如图3B所示,实验结果表明,肺成纤维细胞在细胞AR信号通路激活条件下,ACE2和TMPRSS2在缺氧与常氧条件下无明显差异。
综上,分析新型冠状肺炎重症患者和新型冠状肺炎未感染者的单细胞转录组测序数据发现成纤维细胞中ACE2和TMPRSS2基因的整体表达水平低下且感染者和未感染者组间无明显差异;体外实验研究也验证了在低氧和常氧条件下肺成纤维细胞中的ACE2 和TMPRSS2基因组间无明显差异;这也确证了ACE2和TMPRSS2基因并不参与重症的炎症因子风暴。
实施例4
人肺成纤维细胞HFL1(购自Procell普诺赛,货号CL-0106)在低氧(专用低氧培养箱培养条件:37℃,1% O2)条件下,用HFL1培养基(Ham’s F-12K + 10%FBS + 1%P/S)进行培养,随后使用RIPA组织/细胞裂解液与PMSF试剂进行蛋白质提取;然后根据抗体和抗原之间的专一性作用原理使用Pierce™ Co-Immunoprecipitation Kit 试剂盒进行免疫共沉淀(co-IP)实验;随后对将免疫共沉淀所得结果进行下一步Western bloting实验。
Western bloting实验具体步骤如下:首先,按照配方配制10%SDS分离胶与浓缩胶,样品与加样缓冲液混合,100℃冰浴煮沸5 min,冰浴、离心后用微量加样器等量加入各泳道进行电泳分离,通过SDS-PAGE分离蛋白质,转移至PVDF膜 (Merck Millipore, MA,USA) 并在5%BSA中孵育1小时。将膜在4℃条件下用1:400稀释的一抗HIF-1α和AR温育过夜, 用TBST洗涤3次后与山羊抗兔二抗温育1小时。室温下PBS缓冲液洗涤3次,每次5 min。将膜浸入ECL反应液中,室温1 min。移除液体后,将膜用食品保鲜膜覆盖,于阴暗室中环境下通过线片曝光,显影、定影后观察结果。
结果如图4A、图4B所示,实验结果表明,在人肺成纤维细胞中HIF-1α需要与AR相互结合形成复合物来行使功能。
实施例5
在常氧(37℃,5% CO2)与低氧(37℃,1% O2)环境下培养肺成纤维细胞HFL1(购自Procell普诺赛,货号CL-0106),然后使用HIF-1α抑制剂与AR抑制剂各自或联合处理肺成纤维细胞HFL1。48h后,收集处理细胞;进而通过实时荧光定量PCR(qPCR)检测相关基因的表达水平。
HIF-1α抑制剂KC7F2,LW 6,PX-478 2HCI(购自Selleck,货号:S7946,S8441,S7612)。AR抑制剂Enzalutamide,Apalutamide,Darolutamide,Galeterone,AZD3514(购自Selleck,货号:S1250,S2840,S7559,S2803,S7040), Proxalutamide(源自发明专利,公开号:CN106810542A),SHR-3680 (源自发明专利,公开号:CN103958480B)。HFL1细胞专用培养基(购自Procell普诺赛,货号:CM-0106)。不同处理组添加抑制剂成分如表1。
表1 组1-组14中添加抑制剂成分
组别 | 抑制剂成分 |
组1 | 无HIF-1α抑制剂或AR抑制剂 |
组2 | HIF-1α抑制剂1,KC7F2 20 μM。(购自Selleck,货号:S7946) |
组3 | HIF-1α抑制剂2,LW 6 20 μM。(购自Selleck,货号:S8441) |
组4 | HIF-1α抑制剂3,PX-478 2HCI 20 μM。 (购自Selleck,货号:S7612) |
组5 | AR抑制剂1,Enzalutamide 10 μM。(购自Selleck,货号:S1250) |
组6 | AR抑制剂2,Apalutamide 10 μM。(购自Selleck,货号:S2840) |
组7 | AR抑制剂3,Darolutamide 10 μM。(购自Selleck,货号:S7559) |
组8 | AR抑制剂4,Galeterone 10 μM。(购自Selleck,货号:S2803) |
组9 | AR抑制剂5,AZD3514 10 μM。(购自Selleck,货号:S7040) |
组10 | AR抑制剂6,Proxalutamide 10μM。(源自发明专利,公开号:CN106810542A) |
组11 | AR抑制剂7,SHR-3680 10μM。(源自发明专利,公开号:CN103958480B) |
组12 | HIF-1α抑制剂1(20 μM)与AR抑制剂1(10 μM)联合处理1 |
组13 | HIF-1α抑制剂2(20 μM)与AR抑制剂6(10 μM)联合处理2 |
组14 | HIF-1α抑制剂3(20 μM)与AR抑制剂7(10 μM)联合处理3 |
实验结果如图5A-5H所示,在常氧条件下,两类抑制剂不影响相关基因(IL6、ELN、VCAN、VEGFA、MMP2、ADAMTS4、MMP13、COL3AS1)的表达水平。然而,相对于常氧条件,低氧条件下相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)表达水平显著增加。此外,在低氧条件下,两类抑制剂可使得相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)的表达水平明显降低。具体表明,HIF-1α抑制剂单独处理组,AR抑制剂单独处理组,以及HIF-1α抑制剂与AR抑制剂联合处理组都能够有效抑制相关基因的表达。结果说明,HIF-1α抑制剂与AR抑制剂可以通过抑制HIF-1α与AR的表达从而影响两者的相互结合从而减少其共同结合在相关基因的启动子区域上,进而影响相关基因的转录进程降低相关基因的表达水平。
实施例6
通过添加雄激素(双氢睾酮),探究AR通路激活条件下,抑制剂对相关基因的调节。
在缺氧(37℃,1% O2)条件下,添加双氢睾酮(10nM,购自Sigma-Aldrich)的培养基培养不同组别抑制剂(如实施例5中表1所示)处理人的肺成纤维细胞HFL1,48h后,收集细胞,最后通过实时荧光定量PCR(qPCR)检测相关基因的表达水平。
实验结果如图6A-6H所示,在低氧与细胞AR信号通路激活的条件下,两类抑制剂都能有效降低相关基因(IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA)的表达水平。结果表明,肺成纤维细胞在细胞AR信号通路激活条件下,HIF-1α抑制剂能够通过抑制自身基因表达影响相关基因的表达;同时,AR抑制剂能够通过影响AR信号通路进而有效抑制相关基因的表达。
实施例7
通过构建病毒性肺炎小鼠模型,探究HIF-1α抑制剂或者AR抑制剂对小鼠病毒性肺炎的影响。
病毒性小鼠肺炎模型的构建:选取6-8周龄、体重18-22g的雄性C57BL/6小鼠进行模型制备。实验动物随机分为以下组别:
组别 | 处理方式 |
组1 | 正常组 |
组2 | 病毒组,无HIF-1α抑制剂或AR抑制剂 |
组3 | HIF-1α抑制剂1,LW 6,10mg/kg,灌胃给药,每天一次,连续5天。 |
组4 | HIF-1α抑制剂2,PX-478 2HCI,100mg/kg,腹腔注射给药一次。 |
组5 | AR抑制剂1,Proxalutamide,100mg/kg,腹腔注射给药一次。 |
组6 | AR抑制剂2,SHR-3680,5mg/kg,灌胃给药,每天一次,连续5天。 |
组7 | LW 6(10mg/kg,灌胃给药,每天一次,连续5天)联合SHR-3680(5mg/kg,灌胃给药,每天一次,连续5天)。 |
其中正常对照组小鼠经5%水合氯醛轻度麻醉后,用50 μl PBS滴鼻,其余各组小鼠经水合氯醛轻度麻醉后,从鼻腔滴入10倍LD50感染量的甲型H1N1流感病毒50 μl。给药组于造模后24 h按照上述方案给药处理。病毒攻击后观察小鼠存活状况,连续14天,统计小鼠死亡情况和体重变化。
表2 小鼠平均存活天数及存活率统计
组别 | 平均存活天数(d) | 存活数(只) | 存活率(%) |
正常组 | 14 | 10 | 100 |
Virus control | 9.1±2.21 | 0 | 0 |
LW6 | 11.5±2.54 | 5 | 50 |
PX-478 2HCI | 11.9±2.81 | 6 | 60 |
Proxalutamide | 11.0±2.83 | 4 | 40 |
SHR-3680 | 11.3±2.87 | 5 | 50 |
LW6 + SHR-3680 | 12.9±2.21 | 8 | 80 |
实验结果如图7A-B所示和表2所示。正常对照组小鼠14天存活率为100%,病毒对照组小鼠14 d存活率为10%,而HIF-1α抑制剂1和2组以及AR抑制剂1和2组小鼠14 d存活率分别为:50%、60%、40%和50%。
同时,给于HIF-1α抑制剂和/或AR抑制剂处理均不同程度地减缓了病毒感染引起的小鼠体重下降,延长了小鼠存活天数。结果表明,HIF-1α抑制剂和/或AR抑制剂处理均显著提高了模型小鼠的存活率。
以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。
Claims (4)
1.AR抑制剂和/或HIF-1α抑制剂在制备预防或治疗中、重症病毒性肺炎药物中的应用,其特征在于,所述抑制剂抑制成纤维细胞中AR与HIF-1α复合物的形成,所述HIF-1α抑制剂选自KC7F2、LW 6、PX-478 2HCI中的一种或多种。
2.根据权利要求1所述的应用,其特征在于,所述抑制剂抑制成纤维细胞中AR与HIF-1α复合物的形成,影响炎症相关基因的表达,所述相关基因选自: IL6、MMP2、MMP13、ADAMTS4、ELN、VCAN、COL3A1、VEGFA。
3.根据权利要求1-2任一所述的应用,所述病毒性肺炎为呼吸道合胞病毒肺炎、甲型流感病毒肺炎、COVID-19新型冠状病毒肺炎。
4.根据权利要求1-2任一所述的应用,其特征在于,所述AR抑制剂选自恩杂鲁胺(Enzalutamide)、阿帕鲁胺(Apalutamide)、达洛鲁胺(Darolutamide)、普克鲁胺(Proxalutamide)、加来特龙(Galeterone)、AZD3514、SHR-3680中的一种或多种。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110248587.8A CN112587665B (zh) | 2021-03-08 | 2021-03-08 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
PCT/CN2022/078698 WO2022188665A1 (zh) | 2021-03-08 | 2022-03-02 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
US17/750,888 US20220313707A1 (en) | 2021-03-08 | 2022-05-23 | Use of ar inhibitor and/or hif-1 a a inhibitor in preparation of medicament |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110248587.8A CN112587665B (zh) | 2021-03-08 | 2021-03-08 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112587665A CN112587665A (zh) | 2021-04-02 |
CN112587665B true CN112587665B (zh) | 2021-06-18 |
Family
ID=75210172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110248587.8A Active CN112587665B (zh) | 2021-03-08 | 2021-03-08 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220313707A1 (zh) |
CN (1) | CN112587665B (zh) |
WO (1) | WO2022188665A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112587665B (zh) * | 2021-03-08 | 2021-06-18 | 苏州大学 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
CN115089711A (zh) * | 2022-04-29 | 2022-09-23 | 苏州翊鹏医药科技有限公司 | HIF-1α抑制剂在雄激素性脱发治疗中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014059031A2 (en) * | 2012-10-09 | 2014-04-17 | President And Fellows Of Harvard College | Nad biosynthesis and precursors in the prevention and treatment of inflammation |
AU2019241257A1 (en) * | 2018-03-29 | 2020-11-26 | Hinova Pharmaceuticals Inc. | Deuterated imidazolidinedione compounds and their uses |
CN110665007A (zh) * | 2019-09-19 | 2020-01-10 | 邦世(苏州)生物医药科技有限公司 | 一种治疗癌症用组合药物及其用途 |
CN112336869B (zh) * | 2020-11-23 | 2021-09-14 | 广东龙帆生物科技有限公司 | HIF-1α蛋白抑制剂在制备预防和/或治疗新型冠状病毒感染的药物中的应用 |
CN112587665B (zh) * | 2021-03-08 | 2021-06-18 | 苏州大学 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
-
2021
- 2021-03-08 CN CN202110248587.8A patent/CN112587665B/zh active Active
-
2022
- 2022-03-02 WO PCT/CN2022/078698 patent/WO2022188665A1/zh active Application Filing
- 2022-05-23 US US17/750,888 patent/US20220313707A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN112587665A (zh) | 2021-04-02 |
WO2022188665A1 (zh) | 2022-09-15 |
US20220313707A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lian et al. | Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study | |
Jang et al. | Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy | |
Singh et al. | A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? | |
Gargaglioni et al. | Let’s talk about sex in the context of COVID-19 | |
CN112587665B (zh) | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 | |
Artigas et al. | In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm | |
Davoudi-Monfared et al. | Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial | |
CN111053909A (zh) | 2019-nCoV3CL水解酶抑制剂与IL-6单抗在制备治疗新冠肺炎药物中的应用 | |
Sun et al. | Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice | |
CN115515560A (zh) | 冠状病毒感染的治疗 | |
CN117187096A (zh) | 用于改善肠屏障功能的大肠杆菌菌株及其应用 | |
Wang et al. | HDAC inhibitor sodium butyrate prevents allergic rhinitis and alters lncRNA and mRNA expression profiles in the nasal mucosa of mice | |
JP2021507921A (ja) | 高サイトカイン血症および重篤なインフルエンザの処置または予防のための方法および化合物 | |
Li et al. | ACE2 suppresses the inflammatory response in LPS-induced porcine intestinal epithelial cells via regulating the NF-κB and MAPK pathways | |
Wang et al. | Angiotensin‑converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression | |
Chen et al. | COVID‑19 in China: From epidemiology to treatment | |
Luca et al. | Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics | |
Tavares et al. | Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial | |
Díaz-Menéndez et al. | Clinical characteristics and outcome of hospitalized elderly patients with COVID-19 after vaccine failure | |
Tamanna et al. | A review of recent progress and control measures of severe coronavirus disease (COVID-19) outbreak | |
Sediqi et al. | A review on pathophysiology and pharmacological treatment of COVID-19 | |
CN109679962A (zh) | Fbn2基因及其应用 | |
Turabian | Natural Experiments that Allow to Study Potential Drugs in Coronavirus Disease 2019 (COVID-19) from the General Practice Level | |
CN109718230A (zh) | 丹酚酸a在制备抗高尿酸血症和抗痛风药物中的应用 | |
Gupta et al. | Adjuvant therapy with Serratiopeptidase and Vitamin D for COVID-19 patients: A new perspective |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211201 Address after: 215006 station jy83, Room 601, building 2, No. 58 Heshun Road, Suzhou Industrial Park, Suzhou, Jiangsu Patentee after: Suzhou molecular intersection biomedical Co.,Ltd. Address before: 215006, ten, 1 Zi street, Jiangsu, Suzhou Patentee before: SOOCHOW University |
|
TR01 | Transfer of patent right |